If you’ve been thinking about trying collagen peptides, it’s a good idea to know what they are and if they’ll make a ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

Oral tablets and injections are both effective ... This medication is a glucagon-like peptide-1 (GLP-1) receptor agonist, which means it can help treat type 2 diabetes by prompting your body ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...